Barriers and Facilitators to the Use of Genomic-Based Targeted Lung Cancer Therapies in the VA: Qualitative Findings

Jennifer Arney; Ashley Helm; Ursula K Braun; G John Chen; Teresa G Hayes

Barriers and Facilitators to the Use of Genomic-Based Targeted Lung Cancer Therapies in the VA: Qualitative Findings

Fed Pract. 2018 Feb;35(Suppl 1):S53-S57.

Authors

Jennifer Arney¹, Ashley Helm¹, Ursula K Braun¹, G John Chen¹, Teresa G Hayes¹

Affiliation

¹ is a Health Services Researcher, is a Project Coordinator and Health Services Researcher, is the Director of Palliative Care, and is the Chief of Hematology-Oncology Section, all at Michael E. DeBakey VAMC in Houston, Texas. Dr. Braun is an Associate Professor of Medicine and Dr. Hayes is an Associate Professor of Medicine and Program Director of the Hematology-Oncology Fellowship Program, both at Baylor College of Medicine in Houston. is a Professor of Medicine, Division Director in the Division of Health Services Research, and Director in the Office of Scientific, Academic, and Research Mentoring (OSARM), all in the Department of Internal Medicine at the University of Kansas Medical Center in Kansas City. Dr. Arney is an Assistant Professor in the Department of Sociology at University of Houston-Clear Lake in Houston.

PMID: 30766390
PMCID: PMC6375515

Abstract

Reflexive testing, standardization of the mutation test ordering procedure and results reporting, and elimination of the preauthorization requirements could facilitate the utilization of targeted therapies.